AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...

This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients ...

The pharma giant has received the CDSCO nod to import sodium zirconium cyclosilicate powder for oral suspension (Lokelma) in ...

AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the shares very undervalued. When investing, your capital is at risk.

With this approval, durvalumab can now be used for treating patients with limited-stage small cell lung cancer (LS-SCLC) ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...

is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM ...

The AstraZeneca share price forecast stands at $89.94, signifying a potential upside of 22% in the share price. See more AZN analyst ratings Disclosure AstraZeneca NewsMORE Related Stocks Indices ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...

AstraZeneca’s (LSE: AZN) share price remains significantly down from its 3 September 12-month traded high of £133.38. Such a drop could signal that the pharmaceuticals giant is fundamentally worth ...